Expert Financial Analysis and Reporting

Northwest Biotherapeutics announced today that the Company will host a conference call and webcast  with CEO Linda Powers today, May 27, 2014, at 4:30 p.m. Eastern time to review the early results of the Phase I/II DCVax®-Direct Trial announced this morning and answer questions. Participants must register in order to participate in the conference call.  […]

Investment Conclusion The ASCO abstract on DCVax-Direct was released last night. It contains only a description of the drug and the goals of the phase 1/2 trial. This abstract was submitted some months ago and describes the basic structure and goals of the trial. It does not give any specific patient results. This trial is […]

This Has Been a Tough Correction The recent sharp market correction and rotation out of growth stocks like biotechnology and technology has had a major impact on the small biotechnology names that I specialize in. The correction has been stomach churning for me even though I have been through this many times before. I am […]

Purpose of New Financing Northwest Biotherapeutics just announced a financing in which a single institutional investor bought $15 million of stock at a price of $6.60 which is an 8% discount to the closing price on April 9th. The same investor has the right to purchase an additional $17 million of stock at $7.50 over […]

Before I Get Into This Article, a Word to My Subscribers I want to apologize to my subscribers for a software error that resulted in seven e-mails being sent out to alert subscribers that I had published a new company report today. There should have been just one. We have just implemented this e-mail alert […]

Purpose of This Blog The approval of DCVax-L under the hospital exemption early access program was a stunning positive in my judgment. However, this is the first product made by an American company that has gained approval under this new law that was just passed in 2011. Because of this, there is obviously no prior […]

Overview Northwest Biotherapeutics CEO Linda Powers made a presentation yesterday in which she addressed the bear case that has resulted in significant pressure on the stock in the last two weeks in particular and for the last two years in general. In my opinion, she effectively debunked a weak bear argument, but you be the […]

I have found that there are some very smart people out there who have interesting questions and perspectives concerning my articles. I periodically share with subscribers questions asked of me and my response. Also, some subscribers have a different perspective or additional insights beyond mine that I find informative. Sharing this information is the purpose […]

Back From BIO CEO Conference I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria in New York City. Through attending presentations or one on one meetings,  I heard presentations from Advanced Cell Technology ACTC), Advaxis (ADXS), Agenus (AGEN), Alexion (ALXN) , Alkermes (ALKM), Aradigm (ARDM), Athersys (ATHX), Celator […]

In my writing, I have found that there are some very smart people out there who have interesting questions and perspectives. I have decided to periodically share with subscribers questions asked of me and my response. Also, I will include comments on my articles that I find informative. This is the purpose of SmithOnStocks Mailbox. […]